Wednesday, July 8, 2026

Drug profile · INN

fenfluramine

fenfluramine (FINTEPLA) is a serotonin 2c (5-ht2c) receptor agonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Nervous system (N03) N03
US status approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — fenfluramine
US status
approved
Class
Nervous system (N03)
Route
ORAL
Patents
0
Programs
3
Data quality
0.84

Quick answer

fenfluramine (FINTEPLA) is a serotonin 2c (5-ht2c) receptor agonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN fenfluramine
Brand FINTEPLA
Mechanism Serotonin 2c (5-HT2c) receptor agonist
Therapeutic class Nervous system (N03)
Route ORAL
Formulation SOLUTION
ATC code N03

Mechanism of action

Serotonin 2c (5-HT2c) receptor agonist

Approval history

Authority Status Date
FDA approved
EMA approved
TGA approved

Pipeline programs

  1. ZX008 (Fenfluramine Hydrochloride) Phase 3 · International Peace Maternity · Dravet Syndrome
  2. Fenfluramine Phase 1 · BRIGHT MINDS BIOSCIENCES · Cocaine-Related Disorders
  3. Fenfluramine Approved · United Therapeutics Europe · Cognitive Function

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Frequently asked questions

What is fenfluramine?

fenfluramine (FINTEPLA) is a serotonin 2c (5-ht2c) receptor agonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for fenfluramine?

FINTEPLA is a marketed brand name for fenfluramine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of fenfluramine?

fenfluramine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.